secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2025-04-17T23:59:59+00:00
Accession:  0000886163-25-000020
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ligand subsidiary Pelthos to merge with Channel Therapeutics; $50M capital raise
--------------------------------------------------------------------------------

- Channel to acquire 100% of Pelthos; combined company renamed Pelthos Therapeutics, listing as PTHS on NYSE American.
- Total $50M equity raised: $18M from Ligand, $32M from Murchinson-led investor group.
- Ligand retains 13% royalty on worldwide sales of ZELSUVMI, FDA-approved for Molluscum contagiosum.
- Scott Plesha to become CEO, Frank Knuettel CFO; board includes two Ligand appointees.
- Transaction expected to close summer 2025, subject to customary conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616325000020/0000886163-25-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616325000020/lgnd-20250416.htm
  HTML page:      https://secwatch.observer/filing/0000886163-25-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer